Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 11, 2007, Pages 3099-3104

  Deskus, Jeffrey A ^a   Epperson, James R ^a   Sloan, Charles P ^a   Cipollina, Joseph A ^a   Dextraze, Pierre ^a   Qian Cutrone, Jingfang ^a   Gao, Qi ^a   Ma, Baoqing ^a   Beno, Brett R ^a   Mattson, Gail K ^a   Molski, Thaddeus F ^a   Krause, Rudolph G ^a   Taber, Matthew T ^a   Lodge, Nicholas J ^a   Mattson, Ronald J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Homotryptamine; Serotonin transporter; SSRI

Indexed keywords

AMINE; CYCLOHEXENYLAMINE DERIVATIVE; INDOLE; INDOLE TETRAHYDROPYRIDINE DERIVATIVE; N METHYL TETRAHYDROPYRID 4 YL INDOLE DERIVATIVE; N,N DIMETHYLAMINE; N,N DIMETHYLAMINO CYCLOHEXEN 4 YL INDOLE DERIVATIVE; NITRILE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG CONFORMATION; DRUG DETERMINATION; DRUG POTENCY; ENANTIOMER; ENERGY; MICRODIALYSIS; NONHUMAN; RAT; STEREOCHEMISTRY;

ANIMALS; CYCLOHEXENES; FLUOXETINE; HUMANS; INDOLES; MICRODIALYSIS; MOLECULAR CONFORMATION; PYRIDINES; RATS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TRYPTAMINES;

RATTUS;

EID: 34247877756     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.03.040     Document Type: Article

References (30)

1. Ananth J. Psychother. Psychosom. 67 (1998) 61
2. Rocco V.P., Spinazze P.G., Kohn T.J., Honigschmidt N.A., Nelson D.L., Wainscott D.B., Ahmad L.J., Shaw J., Threlkeld P.G., Wong D.T., and Takeuchi K. Bioorg. Med. Chem. Lett. 14 (2004) 2653
3. Oficialdegui A.M., Martinez J., Perez S., Hears B., Irurzun M., Palop J.A., Tordera R., Lasheras B., del Rio J., and Monge A. Farmaco 55 (2000) 345
4. Evrard D.A., Zhou P., Yi S., Zhow D., Smith D., Sullivan K.M., Hornby G.A., Scheckter L.E., Andree T.H., and Mewshaw R.E. Bioorg. Med. Chem. Lett. 15 (2005) 911
5. Ryckmans T., Balancon L., Berton O., Genicot C., Lamberty Y., Lallemand B., Pasau P., Pirol N., Quere L., and Talaga P. Bioorg. Med. Chem. Lett. 12 (2002) 261
6. Ryckmans T., Berton O., Grimee R., Kogej T., Lamberty Y., Pasau P., Talaga P., and Genicot C. Bioorg. Med. Chem. Lett. 12 (2002) 3195
7. Euvrard C.R., and Boissier J.R. Eur. J. Pharmacol 63 (1980) 65
8. Guillaume J., Dumont C., Laurent J., and Nedelec L. Eur. J. Med. Chem. 22 (1987) 33
9. Macor J.E., Burkhart C.A., Heym J.H., Ives J.L., Lebel L.A., Newman M.E., Neilson J.A., Ryan K., Schulz D.W., Torgersen L.K., and Koe B.K. J. Med. Chem. 33 (1990) 2087
10. Cole D.C., Ellingboe J.W., Lennox W.J., Mazandarani H., Smith D.L., Stock J.R., Zhang G., Zhou P., and Schechter L.E. Bioorg. Med. Chem. Lett. 15 (2005) 379
11. Schmitz W.D., Denhart D.J., Brenner A.B., Ditta J.L., Mattson R.J., Mattson G.K., Molski T.F., and Macor J.E. Bioorg. Med. Chem. Lett. 15 (2005) 1619
12. Denhart D.J., Mattson R.J., Ditta J.L., and Macor J.E. Tetrahedron Lett. 45 (2004) 3803
13. Mattson R.J., Catt J.D., Denhart D.J., Deskus J.A., Ditta J.L., Higgins M.A., Marcin L.R., Sloan C.P., Beno B.R., Gao Q., Cunningham M.A., Mattson G.K., Molski T.F., Taber M.T., and Lodge N.J. J. Med. Chem. 48 (2005) 6023
14. 6): δ 8.26 (s, 1H), 7.56 (d, J = 8.4, 1H), 7.50 (s, 1H), 7.38 (m, 1H), 6.22 (m, 1H), 2.60 (m, 1H), 2.27 (s, 6H), 2.46 (m, 3H), 2.21 (m, 1H), 2.05 (m, 1H), and 1.55 (m, 1H).
15. Chen F., Larsen M.B., Sanchez C., and Wiborg O. Eur. Neuropsychopharamacol. 15 (2005) 193
16. 2/12% ethanol with 0.1% diethylamine, 50 mL/min @ 150 bar, peak 2 corresponds to R-6a.
17. Full crystallographic data have been deposited to the Cambridge Crystallographic Data Center (CCDC reference number 615920). Copies of the data can be obtained free of charge via the internet at http://www.ccdc.cam.ac.uk.
18. 50 > 500. n = 5 for compound 6a.
19. Analytical data for (R)-3-(4-(dimethylamino)cyclohex-1-enyl)-1H-indole-5-carbonitrile, compound R-6a: HPLC purity: >98%; >99%ee; Optical rotation: +51.9 (methanol, c = 3.0 mg/mL).
20. 50 data was determined from a 20-point curve. Non-specific binding was defined using 10 μM Fluoxetine for SERT, 100 μM Desipramine for NET, and 10 μM GBR-12935 for DAT.
21. Taber M.T., Wright R.N., Molski T.F., Clarke W.J., Brassil P.J., Denhart D.J., Mattson R.J., and Lodge N.J. Pharmacol. Biochem. Behav. 80 (2005) 521
22. g The RMS fitting of (S)-citalopram to sertraline included a fourth pair of points corresponding to the centroids of the fluorophenyl ring in (S)-citalopram, and the non-chlorinated phenyl ring in sertraline. The superposition shown in Figure 7 was generated by RMS fitting the low-energy conformers of R-6a, S-6a, 3, and 4 to the sertraline reference conformer as described above for R-6a and S-6a. In both figures, all other compounds were fit to sertraline, even though it is not shown explicitly in Figure 7.
23. Mohamadi F., Richards N.G.J., Guida W.C., Liskamp R., Lipton M., Caufield C., Chang G., Hendrickson T., and Still W.C. J. Comput. Chem. 11 (1990) 440
24. Jorgensen W.L., Maxwell D.S., and Tirado-Rives J. J. Am. Chem. Soc. 118 (1996) 11225
25. Still W.C., Tempczyk A., Hawley R.C., and Hendrickson T.A. J. Am. Chem. Soc. 112 (1990) 6127
26. Polak E., and Ribiere G. Rev. Fr. Inf. Rech. Oper. 16 (1969) 35
27. See: Jaguar 6.5 Operating Manual; Schrodinger, LLC: New York, NY, 2005, and references therein.
28. Hehre W.J., Radom L., Schleyer P.v.R., and Pople J.A. Ab Initio Molecular Orbital Theory (1986), John Wiley, New York Chapter 4
29. Gundertofte K., Bøgesø K.P., and Liljefors T. A Stereoselective Pharmacophoric Model of the Serotonin Re-Uptake Site. In: van de Waterbeemd H., Testa B., and Folkers G. (Eds). Computer-Assisted Lead Finding and Optimization: Current Tools for Medicinal Chemistry (1997), Verlag Helvetica Chimica Acta, Basel, Switzerland 443-459
30. In-house results.